Our Company

Guided by Deep
Scientific Expertise &
Driven by a Passion
to Deliver

We are focused on harnessing the power of the TGF-beta superfamily, the target-rich biology behind the body’s remarkable capacity for cellular growth and repair. Our insights and protein engineering capabilities enable us to design first- and best-in-class candidates for serious and rare diseases. Our lead product, luspatercept, is being evaluated in two global Phase 3 studies in partnership with Celgene to treat chronic anemia in MDS and beta-thalassemia. We are also advancing clinical programs for neuromuscular diseases and cancer.

Read More

A New Approach to Engaging the Body’s Ability to Rebuild and Repair

We Are Building a Rich Pipeline Based on Leadership in TGF-Beta Biology


Hematology

Luspatercept

Hematology

Luspatercept
Preclinical Phase 1 Phase 2 Phase 3
 
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
MEDALIST Study
Long-Term Extension Study
First-Line Lower-Risk MDS Cohorts
Beta-Thalassemia
Beta-Thalassemia
BELIEVE Study
Long-Term Extension Study
NTD Ph 2 Study (Planned)
Myelofibrosis
Myelofibrosis
Ph 2 Study (Planned)


Preclinical Phase 1 Phase 2 Phase 3
 
Myelofibrosis
Sotatercept
 
Myelofibrosis
Investigator-Sponsored Study


Neuromuscular

ACE-083
Preclinical Phase 1 Phase 2 Phase 3
 

Neuromuscular

ACE-083
 
FSH Muscular Dystrophy
FSH Muscular Dystrophy
Part 1 (Ongoing)
Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease
Ph 2 Study (Planned)


Oncology

Dalantercept
Preclinical Phase 1 Phase 2 Phase 3
 
Renal Cell Carcinoma

Oncology

Dalantercept
 
Renal Cell Carcinoma
DART Study

Acceleron

News